Clinical trial readout dates for Biohaven Ltd., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.
| Phase 2 BHV-7000 Focal Epilepsy · NCT06443463 | December 2026 Enrolling |
| Phase 2/3 BHV-7000 Focal Epilepsy · NCT06132893 | December 2026 Ongoing |
| Phase 2/3 BHV-8000 10mg Parkinson Disease · NCT06976268 | August 2027 Recruiting |
| Phase 3 BHV-1300 Graves Disease · NCT07661056 | January 2028 Recruiting |
| Phase 1/2 BHV-1510 Solid Tumor · NCT06384807 | February 2028 Recruiting |
| Phase 3 BHV-1400 IgA Nephropathy · NCT07642050 | September 2028 Not Yet Recruiting |
| Phase 2/3 BHV-1300 Graves' Disease · NCT07901244 | December 2028 Not Yet Recruiting |
Biohaven Ltd. reported $161M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-10-29). Its net loss for that quarter was $129M; at that rate the cash would last about 1 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Reg FD Disclosure — often a data announcement | 2026-11-16 |
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-10-29 |
| 8-K Reg FD Disclosure — often a data announcement | 2026-10-22 |